Roles of CYP2C19 Gene Polymorphisms in Susceptibility to POAG and Individual Differences in Drug Treatment Response
The aim of this study was to investigate the roles of cytochrome P450 2C19 (CYP2C19) polymorphisms in primary open-angle glaucoma (POAG) susceptibility and individual responses to drug treatment. This case-control study consisted of 93 cases with POAG and 125 controls. Polymerase chain reaction-rest...
Gespeichert in:
| Veröffentlicht in: | Medical science monitor 2016-01, Vol.22, p.310-315 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 315 |
|---|---|
| container_issue | |
| container_start_page | 310 |
| container_title | Medical science monitor |
| container_volume | 22 |
| creator | Liu, Xiang-Long Jia, Qiu-Ju Wang, Li-Na Liu, Zong-Ming Liu, Hai Duan, Xuan-Chu Lyu, Xue-Man |
| description | The aim of this study was to investigate the roles of cytochrome P450 2C19 (CYP2C19) polymorphisms in primary open-angle glaucoma (POAG) susceptibility and individual responses to drug treatment.
This case-control study consisted of 93 cases with POAG and 125 controls. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was used to analyze CYP2C19 single-nucleotide polymorphisms (SNPs). After timolol treatment, patients were classified into side effect (SE) group and non-side effect (NSE) group. According to drug treatment responses, patients were divided into 3 groups: excellent group (Ex) (IOP ≥8 mm Hg); utility group (Ut) (5 0.05). Frequencies of extensive metabolizer phenotype and poor metabolizer phenotype or poor metabolizer phenotype and intermediate metabolizer phenotype were significantly different between the SE group and NSE group (both P |
| doi_str_mv | 10.12659/MSM.894868 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4737058</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1761467991</sourcerecordid><originalsourceid>FETCH-LOGICAL-c381t-4149ea0aff31f8f566d3053ff5ba777f790c30265420c8d5c264d27d22e246793</originalsourceid><addsrcrecordid>eNpVUU1PGzEUtKpWBUJPvVc-VqpC_bW291IJBQiRgohIOPRkObvP4GrX3tq7SPn3LISi9PSe9ObNjGYQ-krJGWWyKH_erG_OdCm01B_QMZWCT7kqyMeD_Qid5PyHEKYlKT6jIyY1Y6KkxyjfxQYyjg7Pfq_YjJZ4DgHwKja7Nqbu0ec2Yx_wesgVdL3f-sb3O9xHvLo9n2MbarwItX_y9WAbfOGdgwShgtenizQ84E0C27cQenwHuYshwyn65GyT4cvbnKD7q8vN7Hq6vJ0vZufLacU17aeCihIssc5x6rQrpKw5KbhzxdYqpZwqScXJmIBgpNJ1UTEpaqZqxoAJqUo-Qb_2vN2wbaGuRg_JNqZLvrVpZ6L15v9L8I_mIT4ZobgihR4Jvr8RpPh3gNyb1o8xNI0NEIdsqJL0RamkI_THHlqlmHMC9y5DiXmtyYw1mX1NI_rbobN37L9e-DPk5o34</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1761467991</pqid></control><display><type>article</type><title>Roles of CYP2C19 Gene Polymorphisms in Susceptibility to POAG and Individual Differences in Drug Treatment Response</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>Liu, Xiang-Long ; Jia, Qiu-Ju ; Wang, Li-Na ; Liu, Zong-Ming ; Liu, Hai ; Duan, Xuan-Chu ; Lyu, Xue-Man</creator><creatorcontrib>Liu, Xiang-Long ; Jia, Qiu-Ju ; Wang, Li-Na ; Liu, Zong-Ming ; Liu, Hai ; Duan, Xuan-Chu ; Lyu, Xue-Man</creatorcontrib><description>The aim of this study was to investigate the roles of cytochrome P450 2C19 (CYP2C19) polymorphisms in primary open-angle glaucoma (POAG) susceptibility and individual responses to drug treatment.
This case-control study consisted of 93 cases with POAG and 125 controls. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was used to analyze CYP2C19 single-nucleotide polymorphisms (SNPs). After timolol treatment, patients were classified into side effect (SE) group and non-side effect (NSE) group. According to drug treatment responses, patients were divided into 3 groups: excellent group (Ex) (IOP ≥8 mm Hg); utility group (Ut) (5 <IOP ≤8 mm Hg), and ineffective group (In) (IOP ≤5 mm Hg). Data analysis was performed using SPSS software.
We found no statistical differences in the alleles and genotypes frequencies of CYP2C19 between the case group and the control group (both P>0.05). Frequencies of extensive metabolizer phenotype and poor metabolizer phenotype or poor metabolizer phenotype and intermediate metabolizer phenotype were significantly different between the SE group and NSE group (both P<0.05). The distribution of intermediate metabolizer phenotype and extensive metabolizer phenotype were significantly different among Ex group, Ut group, and In group (all P<0.05).
We found no evidence that CYP2C19 polymorphisms are associated with susceptibility to POAG. However, different CYP2C19 metabolizer phenotypes were identified and observed to have important effects on the individual differences in drug treatment response.</description><identifier>ISSN: 1643-3750</identifier><identifier>ISSN: 1234-1010</identifier><identifier>EISSN: 1643-3750</identifier><identifier>DOI: 10.12659/MSM.894868</identifier><identifier>PMID: 26822491</identifier><language>eng</language><publisher>United States: International Scientific Literature, Inc</publisher><subject>Adult ; Aged ; Case-Control Studies ; Cytochrome P-450 CYP2C19 - genetics ; Female ; Gene Frequency - genetics ; Genetic Predisposition to Disease ; Glaucoma, Open-Angle - drug therapy ; Glaucoma, Open-Angle - enzymology ; Glaucoma, Open-Angle - genetics ; Humans ; Lab/In Vitro Research ; Male ; Middle Aged ; Phenotype ; Polymorphism, Single Nucleotide - genetics ; Timolol - adverse effects ; Timolol - therapeutic use ; Treatment Outcome ; Young Adult</subject><ispartof>Medical science monitor, 2016-01, Vol.22, p.310-315</ispartof><rights>Med Sci Monit, 2016 2016</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c381t-4149ea0aff31f8f566d3053ff5ba777f790c30265420c8d5c264d27d22e246793</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737058/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737058/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26822491$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liu, Xiang-Long</creatorcontrib><creatorcontrib>Jia, Qiu-Ju</creatorcontrib><creatorcontrib>Wang, Li-Na</creatorcontrib><creatorcontrib>Liu, Zong-Ming</creatorcontrib><creatorcontrib>Liu, Hai</creatorcontrib><creatorcontrib>Duan, Xuan-Chu</creatorcontrib><creatorcontrib>Lyu, Xue-Man</creatorcontrib><title>Roles of CYP2C19 Gene Polymorphisms in Susceptibility to POAG and Individual Differences in Drug Treatment Response</title><title>Medical science monitor</title><addtitle>Med Sci Monit</addtitle><description>The aim of this study was to investigate the roles of cytochrome P450 2C19 (CYP2C19) polymorphisms in primary open-angle glaucoma (POAG) susceptibility and individual responses to drug treatment.
This case-control study consisted of 93 cases with POAG and 125 controls. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was used to analyze CYP2C19 single-nucleotide polymorphisms (SNPs). After timolol treatment, patients were classified into side effect (SE) group and non-side effect (NSE) group. According to drug treatment responses, patients were divided into 3 groups: excellent group (Ex) (IOP ≥8 mm Hg); utility group (Ut) (5 <IOP ≤8 mm Hg), and ineffective group (In) (IOP ≤5 mm Hg). Data analysis was performed using SPSS software.
We found no statistical differences in the alleles and genotypes frequencies of CYP2C19 between the case group and the control group (both P>0.05). Frequencies of extensive metabolizer phenotype and poor metabolizer phenotype or poor metabolizer phenotype and intermediate metabolizer phenotype were significantly different between the SE group and NSE group (both P<0.05). The distribution of intermediate metabolizer phenotype and extensive metabolizer phenotype were significantly different among Ex group, Ut group, and In group (all P<0.05).
We found no evidence that CYP2C19 polymorphisms are associated with susceptibility to POAG. However, different CYP2C19 metabolizer phenotypes were identified and observed to have important effects on the individual differences in drug treatment response.</description><subject>Adult</subject><subject>Aged</subject><subject>Case-Control Studies</subject><subject>Cytochrome P-450 CYP2C19 - genetics</subject><subject>Female</subject><subject>Gene Frequency - genetics</subject><subject>Genetic Predisposition to Disease</subject><subject>Glaucoma, Open-Angle - drug therapy</subject><subject>Glaucoma, Open-Angle - enzymology</subject><subject>Glaucoma, Open-Angle - genetics</subject><subject>Humans</subject><subject>Lab/In Vitro Research</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Phenotype</subject><subject>Polymorphism, Single Nucleotide - genetics</subject><subject>Timolol - adverse effects</subject><subject>Timolol - therapeutic use</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>1643-3750</issn><issn>1234-1010</issn><issn>1643-3750</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVUU1PGzEUtKpWBUJPvVc-VqpC_bW291IJBQiRgohIOPRkObvP4GrX3tq7SPn3LISi9PSe9ObNjGYQ-krJGWWyKH_erG_OdCm01B_QMZWCT7kqyMeD_Qid5PyHEKYlKT6jIyY1Y6KkxyjfxQYyjg7Pfq_YjJZ4DgHwKja7Nqbu0ec2Yx_wesgVdL3f-sb3O9xHvLo9n2MbarwItX_y9WAbfOGdgwShgtenizQ84E0C27cQenwHuYshwyn65GyT4cvbnKD7q8vN7Hq6vJ0vZufLacU17aeCihIssc5x6rQrpKw5KbhzxdYqpZwqScXJmIBgpNJ1UTEpaqZqxoAJqUo-Qb_2vN2wbaGuRg_JNqZLvrVpZ6L15v9L8I_mIT4ZobgihR4Jvr8RpPh3gNyb1o8xNI0NEIdsqJL0RamkI_THHlqlmHMC9y5DiXmtyYw1mX1NI_rbobN37L9e-DPk5o34</recordid><startdate>20160129</startdate><enddate>20160129</enddate><creator>Liu, Xiang-Long</creator><creator>Jia, Qiu-Ju</creator><creator>Wang, Li-Na</creator><creator>Liu, Zong-Ming</creator><creator>Liu, Hai</creator><creator>Duan, Xuan-Chu</creator><creator>Lyu, Xue-Man</creator><general>International Scientific Literature, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160129</creationdate><title>Roles of CYP2C19 Gene Polymorphisms in Susceptibility to POAG and Individual Differences in Drug Treatment Response</title><author>Liu, Xiang-Long ; Jia, Qiu-Ju ; Wang, Li-Na ; Liu, Zong-Ming ; Liu, Hai ; Duan, Xuan-Chu ; Lyu, Xue-Man</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c381t-4149ea0aff31f8f566d3053ff5ba777f790c30265420c8d5c264d27d22e246793</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Case-Control Studies</topic><topic>Cytochrome P-450 CYP2C19 - genetics</topic><topic>Female</topic><topic>Gene Frequency - genetics</topic><topic>Genetic Predisposition to Disease</topic><topic>Glaucoma, Open-Angle - drug therapy</topic><topic>Glaucoma, Open-Angle - enzymology</topic><topic>Glaucoma, Open-Angle - genetics</topic><topic>Humans</topic><topic>Lab/In Vitro Research</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Phenotype</topic><topic>Polymorphism, Single Nucleotide - genetics</topic><topic>Timolol - adverse effects</topic><topic>Timolol - therapeutic use</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>online_resources</toplevel><creatorcontrib>Liu, Xiang-Long</creatorcontrib><creatorcontrib>Jia, Qiu-Ju</creatorcontrib><creatorcontrib>Wang, Li-Na</creatorcontrib><creatorcontrib>Liu, Zong-Ming</creatorcontrib><creatorcontrib>Liu, Hai</creatorcontrib><creatorcontrib>Duan, Xuan-Chu</creatorcontrib><creatorcontrib>Lyu, Xue-Man</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medical science monitor</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liu, Xiang-Long</au><au>Jia, Qiu-Ju</au><au>Wang, Li-Na</au><au>Liu, Zong-Ming</au><au>Liu, Hai</au><au>Duan, Xuan-Chu</au><au>Lyu, Xue-Man</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Roles of CYP2C19 Gene Polymorphisms in Susceptibility to POAG and Individual Differences in Drug Treatment Response</atitle><jtitle>Medical science monitor</jtitle><addtitle>Med Sci Monit</addtitle><date>2016-01-29</date><risdate>2016</risdate><volume>22</volume><spage>310</spage><epage>315</epage><pages>310-315</pages><issn>1643-3750</issn><issn>1234-1010</issn><eissn>1643-3750</eissn><abstract>The aim of this study was to investigate the roles of cytochrome P450 2C19 (CYP2C19) polymorphisms in primary open-angle glaucoma (POAG) susceptibility and individual responses to drug treatment.
This case-control study consisted of 93 cases with POAG and 125 controls. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was used to analyze CYP2C19 single-nucleotide polymorphisms (SNPs). After timolol treatment, patients were classified into side effect (SE) group and non-side effect (NSE) group. According to drug treatment responses, patients were divided into 3 groups: excellent group (Ex) (IOP ≥8 mm Hg); utility group (Ut) (5 <IOP ≤8 mm Hg), and ineffective group (In) (IOP ≤5 mm Hg). Data analysis was performed using SPSS software.
We found no statistical differences in the alleles and genotypes frequencies of CYP2C19 between the case group and the control group (both P>0.05). Frequencies of extensive metabolizer phenotype and poor metabolizer phenotype or poor metabolizer phenotype and intermediate metabolizer phenotype were significantly different between the SE group and NSE group (both P<0.05). The distribution of intermediate metabolizer phenotype and extensive metabolizer phenotype were significantly different among Ex group, Ut group, and In group (all P<0.05).
We found no evidence that CYP2C19 polymorphisms are associated with susceptibility to POAG. However, different CYP2C19 metabolizer phenotypes were identified and observed to have important effects on the individual differences in drug treatment response.</abstract><cop>United States</cop><pub>International Scientific Literature, Inc</pub><pmid>26822491</pmid><doi>10.12659/MSM.894868</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1643-3750 |
| ispartof | Medical science monitor, 2016-01, Vol.22, p.310-315 |
| issn | 1643-3750 1234-1010 1643-3750 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4737058 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; PubMed Central |
| subjects | Adult Aged Case-Control Studies Cytochrome P-450 CYP2C19 - genetics Female Gene Frequency - genetics Genetic Predisposition to Disease Glaucoma, Open-Angle - drug therapy Glaucoma, Open-Angle - enzymology Glaucoma, Open-Angle - genetics Humans Lab/In Vitro Research Male Middle Aged Phenotype Polymorphism, Single Nucleotide - genetics Timolol - adverse effects Timolol - therapeutic use Treatment Outcome Young Adult |
| title | Roles of CYP2C19 Gene Polymorphisms in Susceptibility to POAG and Individual Differences in Drug Treatment Response |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T14%3A44%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Roles%20of%20CYP2C19%20Gene%20Polymorphisms%20in%20Susceptibility%20to%20POAG%20and%20Individual%20Differences%20in%20Drug%20Treatment%20Response&rft.jtitle=Medical%20science%20monitor&rft.au=Liu,%20Xiang-Long&rft.date=2016-01-29&rft.volume=22&rft.spage=310&rft.epage=315&rft.pages=310-315&rft.issn=1643-3750&rft.eissn=1643-3750&rft_id=info:doi/10.12659/MSM.894868&rft_dat=%3Cproquest_pubme%3E1761467991%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1761467991&rft_id=info:pmid/26822491&rfr_iscdi=true |